AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03518411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: One-Session Unified Protocol
Study NCT01785758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex (4 mg/Kg)
Description: Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
Study NCT01785758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/Kg)
Description: Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
Study NCT01699464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286 Ophthalmic Solution 0.5%
Description: Ophthalmic Solution
Study NCT01699464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate ophthalmic solution 0.5%
Description: Ophthalmic Solution
Study NCT04334616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngocope
Description: VDL used for VDL arm
Study NCT04334616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Conventional Laryngocope
Description: Used for Conventional laryngocope arm
Study NCT00476112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant Injection 20 mg/mL
Study NCT01741389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (Circadin)
Study NCT01741389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin (Circadin)
Study NCT06142981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP and PBD-VSEL Stem Cell therapy
Description: The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
Study NCT04378647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction with Brentuximab vedotin (BV)
Description: 3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV
Study NCT04378647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction without Brentuximab Vedotin
Description: 3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy
Study NCT04378647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with Brentuximab Vedotin
Description: Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
Study NCT04378647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation with Brentuximab Vedotin
Description: Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
Study NCT01881152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational campaign
Description: Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
Study NCT01881152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Information on stroke usually delivered at the community level.
Study NCT01662037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
Study NCT01792388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Capsule Form
Study NCT01792388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya Bean oil
Description: Capsule form
Study NCT04087564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music intervention
Description: The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session
Study NCT03448705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Description: Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
Study NCT03448705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)
Description: Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
Study NCT03448705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)
Description: Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
Study NCT04795206 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study NCT02024659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
Study NCT02024659 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients receive placebo (saline solution) 2ml twice daily for 14 days.
Study NCT00721812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1399686
Description: Safety and tolerability dose escalation in normal human volunteers
Study NCT01083199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTINUUM™
Description: Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
Study NCT01755546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3409
Description: Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Study NCT04234945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Capsule
Description: Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
Study NCT04234945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamins W/Iron Tab
Description: Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
Study NCT04333147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Otilimab (GSK3196165)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
Study NCT04333147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARD(s)
Description: Stable dose of csDMARD(s) as standard of care (SoC).
Study NCT00983905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
Study NCT00983905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
Study NCT00983905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
Study NCT00280683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
Study NCT00280683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets that match the L-arginine intervention tablets will be given for three months
Study NCT04077697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR for influenza
Description: influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
Study NCT01169636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
Study NCT01169636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
Study NCT01169636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
Study NCT01169636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
Study NCT01169636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
Study NCT01169636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
Study NCT00632385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan
Description: 40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
Study NCT02743299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handivent Ventilator
Description: CPR with use of a turbine-driven ventilator (Handivent)
Study NCT04366362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualised ACL reconstruction
Description: ACL reconstruction based on anatomical and functional distinctiveness of each patient separately
Study NCT04366362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ACL reconstruction
Description: ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
Study NCT03660397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective endovascular chemical ablation of adrenal gland
Description: Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
Study NCT03660397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional triple antihypertensive treatment
Description: irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
Study NCT03660397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional triple antihypertensive treatment
Description: irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
Study NCT03423368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libramed
Description: Policaptil Gel Retard
Study NCT03423368 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-comparator
Study NCT00883636 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Assessment
Description: Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
Study NCT00883636 — intervention group
Intervention type: OTHER
Intervention: Renal Assessment
Description: Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
Study NCT00883636 — intervention group
Intervention type: OTHER
Intervention: Genetic Evaluation
Description: All patients will undergo genetic screening for all known podocyte gene mutations.
Study NCT00631345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Based Lifestyle Intervention (Phases 1 and 2)
Description: This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
Study NCT00631345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individual Education Program (All Phases)
Description: Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
Study NCT00631345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Directed Maintenance (Phase 3)
Description: Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
Study NCT00631345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Group Maintenance (Phase 3)
Description: The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
Study NCT03419676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
Study NCT02579824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3032b
Description: Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
Study NCT02866396 — intervention group
Intervention type: DRUG
Intervention: Pregabalin
Description: Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
Study NCT02866396 — intervention group
Intervention type: OTHER
Intervention: Naive patient
Description: Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
Study NCT02418715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Aerobics Training
Study NCT01470599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: ORAL TABLET, TWICE DAILY
Study NCT01470599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: ORAL TABLETS, TWICE DAILY
Study NCT03238222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOSAIC
Description: MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
Study NCT00624013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: 50 mg up to 100 mg daily for 6 months
Study NCT03920423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: improvement of arterial depth
Description: deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
Study NCT03120494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir
Description: All subjects will be provided study drug for use daily for one year.
Study NCT00624013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg up to 100 mg daily for 6 months
Study NCT04608136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet intervention
Description: Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
Study NCT04608136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
Study NCT01852032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomosynthesis Breast Scanning
Description: The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
Study NCT01852032 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast CT Scanning
Description: CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan.
Study NCT01501409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium lauryl sulfate
Description: The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.